Genelabs Technologies, Inc.

Smithkline Beecham Corporation

Christopher Don Roberts

Natalia Dyatkina

Jesse Daniel Keicher

Dong-Fang Shi

Ronald Griffith

Janos Botyanszki

Sebastian Johannes Reinhard Liehr

Joseph M Muchowski

Peter H Nelson

Alexander Khorlin

Mark Douglas Velligan

Wentao Zhang

Franz Ulrich Schmitz

Mikail Hakan Gezginci

Ali Dehghani Mohammad Abadi

Martin Robert Leivers

Roopa Rai

Marija Prhavc

Stephen Corey Valdez

Sherwin Sattarzadeh

Irina Slobodov

Joshua Michael Gralapp

Disclosed are compounds having Formula (I) and the compositions and methods relating to these compounds, for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R, m, R, V, W, T, Z, R, Y, and p are disclosed herein. 

N-(6-membered aromatic ring)-amido anti-viral compounds

Disclosed are methods for treating hepatitis C viral infections using deaza-purine compounds of Formula I: wherein W, W, W, Y, R, Z, Y' and R are as defined herein.

Nucleoside derivatives for treating hepatitis C virus infection

Disclosed are &#x3b2;-D-ribofuranosyl-pyrazolo[3,4-d]pyrimidine compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Representative compounds include those having the general formula. 

Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R, m, R, V, W, T, Z, R, Y, and p are disclosed herein. 

N-(5-membered aromatic ring)-amido anti-viral compounds

Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.

Tricyclic-nucleoside prodrugs for treating viral infections

Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

Bicyclic heteroaryl derivatives

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W, W, Y, R, Z, Y' and R are as defined herein.

Nucleoside derivatives for treating Hepatitis C virus infection

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows: and pharmaceutically acceptable prodrugs and salts thereof, where R, R, R, R, W, W, W, Y and Z are as defined herein.

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

5-nitro-nucleoside compounds for treating viral infections

Nucleoside compounds for treating viral infections

Nitrogen-containing heteroaryl derivatives

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, T, Y, W, Wand Ware as defined herein.

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, each of R, Y, W, Wand Ware as defined herein.

Disclosed are methods and intermediates for the preparation of 7-(2'-R-substituted-&#x3b2;-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by afamily virus, such as hepatitis C virus. Such 7-(2&#x2032;-substituted-&#x3b2;-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds are represented by Formula I as follows: wherein, each of R, R, and Rare as defined herein.

[object Object]

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, Y, W, Wand Ware as defined herein.

Growing community of inventors

Belmont, CA, United States of America

Christopher Don Roberts